Clinical Trial Update: Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating carboplatin and nab-paclitaxel with either trastuzumab for HER2-positive or bevacizumab for HER2-negative breast cancer; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: University of California, Irvine | Conditions: Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-10-04